Holen Sie sich die Stockscreener-App
1.40
0.00%
0.00
Vorhandelsmarkt:
1.40
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
1.30M
Relative Volume:
1.42
Marktkapitalisierung:
$149.25M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-4.1176
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+10.24%
1M Leistung:
-30.69%
6M Leistung:
-64.74%
1J Leistung:
-67.21%
1-Tages-Spanne:
$1.365
$1.43
1-Wochen-Bereich:
$1.29
$1.54
52-Wochen-Spanne:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.40 | 144.99M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
131.25 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.75 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
389.94 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.90 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.93 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte Inc. Rebound Backed by Sentiment ShiftPrice Action & Fast Moving Stock Trade Plans - beatles.ru
What makes MaxCyte Inc. stock price move sharplyJuly 2025 Chart Watch & Weekly High Return Forecasts - classian.co.kr
MaxCyte Inc. Testing Reversal Zone on Weekly ChartWeekly Trade Review & Fast Gain Swing Trade Alerts - metal.it
MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks
What machine learning models say about MaxCyte Inc.IPO Watch & Reliable Breakout Forecasts - Newser
Why MaxCyte Inc. is moving todayJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
What MACD and RSI say about MaxCyte Inc.2025 Biggest Moves & Fast Moving Market Watchlists - Newser
Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Maxcyte Stock Soars 10.87% on Insider Buying - AInvest
Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser
Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser
Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 By Investing.com - Investing.com Nigeria
Maxcyte CFO Swirsky buys $64.5k in shares By Investing.com - Investing.com Canada
Brooke William buys Maxcyte (MXCT) shares worth $64,500 By Investing.com - Investing.com Nigeria
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com Australia
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Brooke William buys Maxcyte (MXCT) shares worth $64,500 - Investing.com India
Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com Nigeria
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
MaxCyte signs platform license agreement with Adicet Bio - MSN
Is MaxCyte Inc. Forming a Consolidation BaseMarket Surge Signal for Swing Traders Triggered - beatles.ru
MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte, Inc. shares fall 11.76% premarket after Q2 revenue misses analyst estimates. - AInvest
MaxCyte stock downgraded by William Blair to Market Perform on weak guidance - Investing.com Australia
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):